TY  - GEN
AU  - Gu,Shuyan
AU  - Deng,Jing
AU  - Shi,Lizheng
AU  - Mu,Yiming
AU  - Dong,Hengjin
TI  - Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China
SN  - 1941-837X
PY  - 2016///0704
KW  - Adamantane
KW  - adverse effects
KW  - Body Mass Index
KW  - Cardiovascular Diseases
KW  - economics
KW  - China
KW  - Computer Simulation
KW  - Cost-Benefit Analysis
KW  - Diabetes Mellitus, Type 2
KW  - complications
KW  - Dipeptides
KW  - Dipeptidyl-Peptidase IV Inhibitors
KW  - Disease Progression
KW  - Drug Therapy, Combination
KW  - Female
KW  - Hospital Costs
KW  - statistics & numerical data
KW  - Humans
KW  - Hypoglycemia
KW  - chemically induced
KW  - Hypoglycemic Agents
KW  - Insurance Claim Review
KW  - Kidney Diseases
KW  - Male
KW  - Metformin
KW  - Middle Aged
KW  - Models, Economic
KW  - Quality-Adjusted Life Years
KW  - Sulfonylurea Compounds
N1  - Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.3111/13696998.2015.1049542
ER  -